Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

Author:

Joensuu Heikki1,Eriksson Mikael2,Hall Kirsten Sundby3,Hartmann Jörg T.4,Pink Daniel5,Schütte Jochen6,Ramadori Giuliano7,Hohenberger Peter8,Duyster Justus9,Al‐Batran Salah‐Eddin10,Schlemmer Marcus11,Bauer Sebastian12,Wardelmann Eva13,Sarlomo‐Rikala Maarit14,Nilsson Bengt15,Sihto Harri16,Ballman Karla V.17,Leinonen Mika18,DeMatteo Ronald P.19,Reichardt Peter5

Affiliation:

1. Department of OncologyHelsinki University Central HospitalHelsinki Finland

2. Department of Oncology, Skåne University HospitalLund UniversityLund Sweden

3. Department of Oncology, The Norwegian Radium HospitalOslo University HospitalOslo Norway

4. Section of Medical Oncology, Medical Center 2Christian‐Albrechts‐UniversityKiel Germany

5. Sarkomzentrum Berlin‐BrandenburgHELIOS Klinikum Berlin‐BuchBerlin Germany

6. Schwerpunktpraxis für Onkologie Hämatologie und ambulante TumortherapieDüsseldorf Germany

7. Department of Gastroenterology/EndocrinologyUniversity of GöttingenGöttingen

8. Division of Surgical Oncology and Thoracic SurgeryMannheim University Medical CenterMannheim Germany

9. III Medizinischen KlinikKlinikum rechts der IsarMunich Germany

10. Klinik für Onkologie und Hämatologie amKrankenhaus Nordwest, Frankfurt Germany

11. Department of Internal Medicine IIIUniversity Hospital‐Großhadern, Ludwig Maximilians UniversityMunich Germany

12. Sarcoma Center, West German Cancer CenterUniversity of Duisburg‐EssenEssen Germany

13. Gerhard Domagk Institute of PathologyUniversity Hospital MuensterMuenster Germany

14. Department of PathologyHelsinki University Central HospitalHelsinki Finland

15. Department of SurgerySahlgrenska University HospitalGothenburg Sweden

16. Laboratory of Molecular OncologyBiomedicum, University of HelsinkiHelsinki Finland

17. Mayo ClinicRochester Minnesota

18. 4Pharma LtdTurku Finland

19. Memorial Sloan Kettering Cancer Center, New YorkNew York

Funder

Academy of Finland

Cancer Society of Finland

Helsinki University Research Funds

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3